Preclinical Evaluation of a Novel High-Affinity Radioligand [99mTc]Tc-BQ0413 Targeting Prostate-Specific Membrane Antigen (PSMA)
Abstract
:1. Introduction
2. Results
2.1. Radiolabeling and In Vitro Characterization of [99mTc]Tc-BQ0413
2.2. In Vivo Characterization
3. Discussion
4. Materials and Methods
4.1. Radiochemistry
4.1.1. BQ0413 99mTc-Labeling and Stability Control
4.1.2. 68Ga-Labeling of PSMA-11 for Comparative Studies
4.2. In Vitro Characterization
4.3. In Vivo Assays
4.3.1. Biodistribution in Tumor-Bearing Mice
4.3.2. Binding Specificity to PSMA
4.3.3. Efficacy of Blocking Normal Tissue Uptake
4.3.4. Comparison of Targeting Properties of [99mTc]Tc-BQ0413 and [68Ga]Ga-PSMA-11
4.3.5. Imaging
4.3.6. Dosimetry Estimation
4.4. Data Analysis
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Appendix A
Organ | 1 h | 3 h | 6 h |
---|---|---|---|
Blood | 0.9 ± 0.4 | 0.32 ± 0.05 | 0.16 ± 0.02 |
Salivary gland | 5 ± 1 | 2.3 ± 0.3 | 1.1 ± 0.2 |
Lungs | 3.2 ± 0.5 | 1.8 ± 0.3 | 1.5 ± 0.3 |
Liver | 1.3 ± 0.6 | 0.43 ± 0.07 | 0.26 ± 0.03 |
Spleen | 41 ± 15 | 13 ± 3 | 10 ± 6 |
Pancreas | 1.6 ± 0.3 | 1.1 ± 0.2 | 0.5 ± 0.2 |
Stomach | 0.7 ± 0.2 | 0.5 ± 0.1 | 0.29 ± 0.1 |
Small intestine | 0.5 ± 0.1 | 0.3 ± 0.1 | 0.14 ± 0.02 |
Kidneys | 224 ± 12 | 241 ± 21 | 251 ± 21 |
Tumor | 30 ± 4 | 38 ± 7 | 39 ± 5 |
Muscle | 0.66 ± 0.08 | 0.3 ± 0.1 | 0.17 ± 0.03 |
Bone | 1.0 ± 0.3 | 0.5 ± 0.1 | 0.31 ± 0.03 |
GI tract | 1.4 ± 0.1 | 2.0 ± 0.2 | 1.5 ± 0.4 |
Organ | 1 h | 3 h | 6 h |
---|---|---|---|
Blood | 38 ± 14 | 123 ± 25 | 243 ± 27 |
Salivary gland | 6 ± 1 | 16 ± 2 | 35 ± 4 |
Lungs | 10 ± 1 | 21 ± 4 | 27 ± 4 |
Liver | 26 ± 10 | 85 ± 5 | 152 ± 15 |
Spleen | 0.8 ± 0.2 | 2.8 ± 0.5 | 3.5 ± 0.7 |
Pancreas | 20 ± 3 | 389 ± 9 | 87 ± 45 |
Stomach | 43 ± 10 | 69 ± 6 | 144 ± 31 |
Small intestine | 70 ± 20 | 106 ± 20 | 272 ± 24 |
Kidneys | 0.13 ± 0.01 | 0.17 ± 0.02 | 0.16 ± 0.02 |
Muscle | 46 ± 4 | 123 ± 36 | 236 ± 25 |
Bone | 331 ± 9 | 87 ± 41 | 128 ± 24 |
Organ | PC3-pip (PSMA+) | PC-3 (PSMA−) | SKOV-3 (PSMA−) |
---|---|---|---|
Blood | 0.32 ± 0.05 | 0.5 ± 0.3 | 0.38 ± 0.08 |
Salivary gland | 2.3 ± 0.3 | 3.7 ± 0.9 | 3.1 ± 0.8 |
Lungs | 1.8 ± 0.3 | 2.3 ± 0.4 | 2.5 ± 0.2 |
Liver | 0.43 ± 0.07 | 1.0 ± 0.4 | 0.6 ± 0.1 |
Spleen | 13 ± 3 | 24 ± 11 | 19 ± 7 |
Pancreas | 1.1 ± 0.2 | 1.5 ± 0.9 | 0.9 ± 0.4 |
Stomach | 0.5 ± 0.1 | 2 ± 2 | 0.6 ± 0.1 |
Small intestine | 0.3 ± 0.1 | 0.5 ± 0.3 | 0.5 ± 0.3 |
Kidneys | 241 ± 21 | 254 ± 25 | 300 ± 49 |
Tumor | 38 ± 6 | 3 ± 2 | 0.9 ± 0.3 |
Muscle | 0.3 ± 0.1 | 0.38 ± 0.08 | 0.4 ± 0.1 |
Bone | 0.5 ± 0.1 | 0.5 ± 0.2 | 0.7 ± 0.3 |
GI tract | 2.0 ± 0.2 | 2.2 ± 0.6 | 2.1 ± 0.4 |
Organ | [99mTc]Tc-BQ0413 | [68Ga]Ga-PSMA-11 |
---|---|---|
Blood | 0.9 ± 0.4 | 0.8 ± 0.1 |
Salivary gland | 5 ± 1 | 4.4 ± 0.8 |
Lungs | 3.2 ± 0.5 | 3.2 ± 0.6 |
Liver | 1.3 ± 0.6 | 0.7 ± 0.2 |
Spleen | 41 ± 15 | 28 ± 4 |
Pancreas | 1.6 ± 0.2 | 1.3 ± 0.2 |
Stomach | 0.7 ± 0.2 | 0.8 ± 0.3 |
Small intestine | 0.5 ± 0.1 | 0.5 ± 0.1 |
Kidneys | 224 ± 12 | 226 ± 40 |
Tumor | 30 ± 4 | 20 ± 3 |
Muscle | 0.66 ± 0.08 | 0.54 ± 0.08 |
Bone | 1.0 ± 0.3 | 0.60 ± 0.06 |
GI tract | 1.4 ± 0.1 | 1.6 ± 0.3 |
Organ | [99mTc]Tc-BQ0413 | [68Ga]Ga-PSMA-11 |
---|---|---|
Blood | 38 ± 14 | 26 ± 9 |
Salivary glands | 6 ± 1 | 5 ± 1 |
Lungs | 10 ± 1 | 7 ± 2 |
Liver | 26 ± 10 | 30 ± 14 |
Spleen | 0.8 ± 0.2 | 0.7 ± 0.2 |
Pancreas | 20 ± 3 | 15 ± 3 |
Stomach | 43 ± 10 | 29 ± 11 |
Small intestine | 70 ± 20 | 42 ± 14 |
Kidneys | 0.13 ± 0.01 | 0.09 ± 0.02 |
Muscle | 46 ± 4 | 38 ± 11 |
Bone | 33 ± 9 | 34 ± 7 |
Organ | 1 h | 3 h | 6 h | 24 h |
---|---|---|---|---|
Blood | 0.45 ± 0.10 | 0.17 ± 0.05 | 0.09 ± 0.01 | 0.013 ± 0.004 |
Heart | 0.47 ± 0.08 | 0.18 ± 0.05 | 0.09 ± 0.02 | 0.02 ± 0.01 |
Lungs | 1.4 ± 0.1 | 0.8 ± 0.1 | 0.44 ± 0.09 | 0.04 ± 0.01 |
Liver | 0.37 ± 0.02 | 0.17 ± 0.08 | 0.09 ± 0.01 | 0.014 ± 0.004 |
Spleen | 3 ± 13 | 1.8 ± 0.4 | 1.1 ± 0.5 | 0.09 ± 0.03 |
Pancreas | 0.79 ± 0.03 | 0.7 ± 0.3 | 0.38 ± 0.06 | 0.03 ± 0.01 |
Kidneys | 188 ± 8 | 228 ± 33 | 223 ± 23 | 31 ± 10 |
Muscle | 0.42 ± 0.01 | 0.16 ± 0.04 | 0.08 ± 0.01 | 0.02 ± 0.01 |
Bone | 1.2 ± 0.2 | 0.58 ± 0.10 | 0.42 ± 0.07 | 0.20 ± 0.01 |
Stomach | 0.03 ± 0.01 | 0.016 ± 0.002 | 0.012 ± 0.001 | 0.007 ± 0.001 |
Small intestine | 0.33 ± 0.03 | 0.4 ± 0.2 | 0.3 ± 0.1 | 0.3 ± 0.3 |
Upper large intestine | 1.2 ± 0.2 | 1.2 ± 0.5 | 0.7 ± 0.2 | 0.3 ± 0.2 |
Large intestine | 0.06 ± 0.02 | 0.17 ± 0.08 | 0.30 ± 0.06 | 0.2 ± 0.1 |
Caecum | 0.05 ± 0.01 | 0.2 ± 0.2 | 0.20 ± 0.2 | 0.2 ± 0.1 |
Carcass | 0.11 ± 0.02 | 0.59 ± 0.07 | 0.8 ± 0.2 | 0.5 ± 0.4 |
References
- Rawla, P. Epidemiology of Prostate Cancer. World J. Oncol. 2019, 10, 63–89. [Google Scholar] [CrossRef] [PubMed]
- Lindenberg, M.L.; Turkbey, B.; Mena, E.; Choyke, P.L. Imaging Locally Advanced, Recurrent, and Metastatic Prostate Cancer: A Review. JAMA Oncol. 2017, 3, 1415–1422. [Google Scholar] [CrossRef]
- Li, M.; Zelchan, R.; Orlova, A. The Performance of FDA-Approved PET Imaging Agents in the Detection of Prostate Cancer. Biomedicines 2022, 10, 2533. [Google Scholar] [CrossRef]
- Mattana, F.; Muraglia, L.; Rajwa, P.; Zattoni, F.; Marra, G.; Chiu, P.K.F.; Heidegger, I.; Kasivisvanathan, V.; Kesch, C.V.; Olivier, J.; et al. Metastatic Sites’ Location and Impact on Patient Management After the Introduction of Prostate-specific Membrane Antigen Positron Emission Tomography in Newly Diagnosed and Biochemically Recurrent Prostate Cancer: A Critical Review. Eur. Urol. Oncol. 2023, 6, 128–136. [Google Scholar] [CrossRef]
- Jones, W.; Griffiths, K.; Barata, P.C.; Paller, C.J. PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy. Cancers 2020, 12, 1367. [Google Scholar] [CrossRef]
- Haberkorn, U.; Eder, M.; Kopka, K.; Babich, J.W.; Eisenhut, M. New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy. Clin. Cancer Res. 2016, 22, 9–15. [Google Scholar] [CrossRef]
- Ponsky, L.E.; Cherullo, E.E.; Starkey, R.; Nelson, D.; Neumann, D.; Zippe, C.D. Evaluation of preoperative ProstaScint™ scans in the prediction of nodal disease. Prostate Cancer Prostatic Dis. 2002, 5, 132–135. [Google Scholar] [CrossRef]
- Zhang, H.; Koumna, S.; Pouliot, F.; Beauregard, J.-M.; Kolinsky, M. PSMA Theranostics: Current Landscape and Future Outlook. Cancers 2021, 13, 4023. [Google Scholar] [CrossRef]
- Neels, O.C.; Kopka, K.; Liolios, C.; Afshar-Oromieh, A. Radiolabeled PSMA Inhibitors. Cancers 2021, 13, 6255. [Google Scholar] [CrossRef]
- Debnath, S.; Zhou, N.; McLaughlin, M.; Rice, S.; Pillai, A.K.; Hao, G.; Sun, X. PSMA-Targeting Imaging and Theranostic Agents—Current Status and Future Perspective. Int. J. Mol. Sci. 2022, 23, 1158. [Google Scholar] [PubMed]
- Hillier, S.M.; Maresca, K.P.; Lu, G.; Merkin, R.D.; Marquis, J.C.; Zimmerman, C.N.; Eckelman, W.C.; Joyal, J.L.; Babich, J.W. 99mTc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen for Molecular Imaging of Prostate Cancer. J. Nucl. Med. 2013, 54, 1369–1376. [Google Scholar] [CrossRef] [PubMed]
- Vallabhajosula, S.; Nikolopoulou, A.; Babich, J.W.; Osborne, J.R.; Tagawa, S.T.; Lipai, I.; Solnes, L.; Maresca, K.P.; Armor, T.; Joyal, J.L.; et al. 99mTc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen: Pharmacokinetics and Biodistribution Studies in Healthy Subjects and Patients with Metastatic Prostate Cancer. J. Nucl. Med. 2014, 55, 1791–1798. [Google Scholar] [CrossRef] [PubMed]
- Wyngaert, T.V.d.; Elvas, F.; Schepper, S.D.; Kennedy, J.A.; Israel, O. SPECT/CT: Standing on the Shoulders of Giants, It Is Time to Reach for the Sky! J. Nucl. Med. 2020, 61, 1284–1291. [Google Scholar] [CrossRef] [PubMed]
- Pepperberg, I.M. Grey parrot (Psittacus erithacus) numerical abilities: Addition and further experiments on a zero-like concept. J. Comp. Psychol. 2006, 120, 1–11. [Google Scholar] [CrossRef] [PubMed]
- Bailey, D.L.; Willowson, K.P. Quantitative SPECT/CT: SPECT joins PET as a quantitative imaging modality. Eur. J. Nucl. Med. Mol. Imaging 2014, 41, 17–25. [Google Scholar] [CrossRef] [PubMed]
- Lundmark, F.; Olanders, G.; Rinne, S.S.; Abouzayed, A.; Orlova, A.; Rosenström, U. Design, Synthesis, and Evaluation of Linker-Optimised PSMA-Targeting Radioligands. Pharmaceutics 2022, 14, 1098. [Google Scholar] [CrossRef] [PubMed]
- Abouzayed, A.; Seitova, K.; Lundmark, F.; Bodenko, V.; Oroujeni, M.; Tolmachev, V.; Rosenström, U.; Orlova, A. 177Lu-labeled PSMA targeting therapeutic with optimized linker for treatment of disseminated prostate cancer; evaluation of biodistribution and dosimetry. Front. Oncol. 2023, 13, 1221103. [Google Scholar] [CrossRef]
- Maurin, M.; Wyczółkowska, M.; Sawicka, A.; Sikora, A.E.; Karczmarczyk, U.; Janota, B.; Radzik, M.; Kłudkiewicz, D.; Pijarowska-Kruszyna, J.; Jaroń, A.; et al. [99mTc]Tc-PSMA-T4—Novel SPECT Tracer for Metastatic PCa: From Bench to Clinic. Molecules 2022, 27, 7216. [Google Scholar]
- Robu, S.; Schottelius, M.; Eiber, M.; Maurer, T.; Gschwend, J.; Schwaiger, M.; Wester, H.-J. Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer. J. Nucl. Med. 2017, 58, 235–242. [Google Scholar] [CrossRef]
- Urbán, S.; Meyer, C.; Dahlbom, M.; Farkas, I.; Sipka, G.; Besenyi, Z.; Czernin, J.; Calais, J.; Pávics, L. Radiation Dosimetry of 99mTc-PSMA I&S: A Single-Center Prospective Study. J. Nucl. Med. 2021, 62, 1075–1081. [Google Scholar] [CrossRef]
- Tran, T.; Engfeldt, T.; Orlova, A.; Sandström, M.; Feldwisch, J.; Abrahmsén, L.; Wennborg, A.; Tolmachev, V.; Karlström, A.E. 99mTc-maEEE-ZHER2:342, an Affibody Molecule-Based Tracer for the Detection of HER2 Expression in Malignant Tumors. Bioconjugate Chem. 2007, 18, 1956–1964. [Google Scholar] [CrossRef] [PubMed]
- Abiraj, K.; Mansi, R.; Tamma, M.-L.; Forrer, F.; Cescato, R.; Reubi, J.C.; Akyel, K.G.; Maecke, H.R. Tetraamine-Derived Bifunctional Chelators for Technetium-99m Labelling: Synthesis, Bioconjugation and Evaluation as Targeted SPECT Imaging Probes for GRP-Receptor-Positive Tumours. Chem.—Eur. J. 2010, 16, 2115–2124. [Google Scholar] [CrossRef] [PubMed]
- Jamous, M.; Tamma, M.L.; Gourni, E.; Waser, B.; Reubi, J.C.; Maecke, H.R.; Mansi, R. PEG spacers of different length influence the biological profile of bombesin-based radiolabeled antagonists. Nucl. Med. Biol. 2014, 41, 464–470. [Google Scholar] [CrossRef]
- Kuo, H.-T.; Merkens, H.; Zhang, Z.; Uribe, C.F.; Lau, J.; Zhang, C.; Colpo, N.; Lin, K.-S.; Bénard, F. Enhancing Treatment Efficacy of 177Lu-PSMA-617 with the Conjugation of an Albumin-Binding Motif: Preclinical Dosimetry and Endoradiotherapy Studies. Mol. Pharm. 2018, 15, 5183–5191. [Google Scholar] [CrossRef] [PubMed]
- Kuo, H.-T.; Pan, J.; Zhang, Z.; Lau, J.; Merkens, H.; Zhang, C.; Colpo, N.; Lin, K.-S.; Bénard, F. Effects of Linker Modification on Tumor-to-Kidney Contrast of 68Ga-Labeled PSMA-Targeted Imaging Probes. Mol. Pharm. 2018, 15, 3502–3511. [Google Scholar] [CrossRef]
- Liu, T.; Liu, C.; Xu, X.; Liu, F.; Guo, X.; Li, N.; Wang, X.; Yang, J.; Yang, X.; Zhu, H.; et al. Preclinical Evaluation and Pilot Clinical Study of Al18F-PSMA-BCH for Prostate Cancer PET Imaging. J. Nucl. Med. 2019, 60, 1284–1292. [Google Scholar] [CrossRef]
- Piron, S.; Verhoeven, J.; Descamps, B.; Kersemans, K.; De Man, K.; Van Laeken, N.; Pieters, L.; Vral, A.; Vanhove, C.; De Vos, F. Intra-individual dynamic comparison of 18F-PSMA-11 and 68Ga-PSMA-11 in LNCaP xenograft bearing mice. Sci. Rep. 2020, 10, 21068. [Google Scholar] [CrossRef]
- Donin, N.M.; Reiter, R.E. Why Targeting PSMA Is a Game Changer in the Management of Prostate Cancer. J. Nucl. Med. 2018, 59, 177–182. [Google Scholar] [CrossRef]
- Barve, A.; Jin, W.; Cheng, K. Prostate cancer relevant antigens and enzymes for targeted drug delivery. J. Control. Release 2014, 187, 118–132. [Google Scholar] [CrossRef]
- Kalidindi, T.M.; Lee, S.-G.; Jou, K.; Chakraborty, G.; Skafida, M.; Tagawa, S.T.; Bander, N.H.; Schoder, H.; Bodei, L.; Pandit-Taskar, N.; et al. A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals. Eur. J. Nucl. Med. Mol. Imaging 2021, 48, 2642–2651. [Google Scholar] [CrossRef]
- Kelloff, G.J.; Choyke, P.; Coffey, D.S. Challenges in clinical prostate cancer: Role of imaging. AJR. Am. J. Roentgenol. 2009, 192, 1455–1470. [Google Scholar] [CrossRef]
- Eckelman, W.C.; Kilbourn, M.R.; Mathis, C.A. Specific to nonspecific binding in radiopharmaceutical studies: It’s not so simple as it seems! Nucl. Med. Biol. 2009, 36, 235–237. [Google Scholar] [CrossRef]
- Bubendorf, L.; Schöpfer, A.; Wagner, U.; Sauter, G.; Moch, H.; Willi, N.; Gasser, T.C.; Mihatsch, M.J. Metastatic patterns of prostate cancer: An autopsy study of 1589 patients. Hum. Pathol. 2000, 31, 578–583. [Google Scholar] [CrossRef] [PubMed]
- Kratochwil, C.; Giesel, F.L.; Leotta, K.; Eder, M.; Hoppe-Tich, T.; Youssoufian, H.; Kopka, K.; Babich, J.W.; Haberkorn, U. PMPA for Nephroprotection in PSMA-Targeted Radionuclide Therapy of Prostate Cancer. J. Nucl. Med. 2015, 56, 293–298. [Google Scholar] [CrossRef] [PubMed]
- Wurzer, A.; Pollmann, J.; Schmidt, A.; Reich, D.; Wester, H.-J.; Notni, J. Molar Activity of Ga-68 Labeled PSMA Inhibitor Conjugates Determines PET Imaging Results. Mol. Pharm. 2018, 15, 4296–4302. [Google Scholar] [CrossRef] [PubMed]
- Divgi, C.R.; Welt, S.; Kris, M.; Real, F.X.; Yeh, S.D.J.; Gralla, R.; Merchant, B.; Schweighart, S.; Unger, M.; Larson, S.M.; et al. Phase I and Imaging Trial of Indium 111-Labeled Anti-Epidermal Growth Factor Receptor Monoclonal Antibody 225 in Patients with Squamous Cell Lung Carcinoma. JNCI J. Natl. Cancer Inst. 1991, 83, 97–104. [Google Scholar] [CrossRef]
- Bai, J.-W.; Qiu, S.-Q.; Zhang, G.-J. Molecular and functional imaging in cancer-targeted therapy: Current applications and future directions. Signal Transduct. Target. Ther. 2023, 8, 89. [Google Scholar] [CrossRef]
- Nicolas, G.P.; Mansi, R.; McDougall, L.; Kaufmann, J.; Bouterfa, H.; Wild, D.; Fani, M. Biodistribution, Pharmacokinetics, and Dosimetry of (177)Lu-, (90)Y-, and (111)In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist (177)Lu-DOTATATE: The Mass Effect. J. Nucl. Med. Off. Publ. Soc. Nucl. Med. 2017, 58, 1435–1441. [Google Scholar] [CrossRef]
- Zhang, J.; Zhang, J.; Xu, X.; Lu, L.; Hu, S.; Liu, C.; Cheng, J.; Song, S.; Zhang, Y.; Shi, L.Q. Evaluation of Radiation dosimetry of 99mTc-HYNIC-PSMA and imaging in prostate cancer. Sci. Rep. 2020, 10, 4179. [Google Scholar] [CrossRef]
- Yang, H.; Gao, Z.; Xu, X.; Liu, C.; Hu, S.; Zhang, J.; Song, S. Dosimetry estimation and preliminary clinical application of [99mTc]Tc-HYNIC-PSMA-XL-2 in prostate cancer. Ann. Nucl. Med. 2023, 37, 60–69. [Google Scholar] [CrossRef]
- Abouzayed, A.; Rinne, S.S.; Sabahnoo, H.; Sörensen, J.; Chernov, V.; Tolmachev, V.; Orlova, A. Preclinical Evaluation of 99mTc-Labeled GRPR Antagonists maSSS/SES-PEG2-RM26 for Imaging of Prostate Cancer. Pharmaceutics 2021, 13, 182. [Google Scholar] [CrossRef]
- Sadre Momtaz, A.; Safarnejad, F. Effective dose to adult patients undergoing renal scans with 99mTc (DMSA, DTPA, EC AND MAG3). Radiat. Prot. Dosim. 2022, 198, 1244–1257. [Google Scholar] [CrossRef]
- Ebrahimnejad Gorji, K.; Abedi Firouzjah, R.; Khanzadeh, F.; Abdi-Goushbolagh, N.; Banaei, A.; Ataei, G. Estimating the Absorbed Dose of Organs in Pediatric Imaging of (99m)Tc-DTPATc-DTPA Radiopharmaceutical using MIRDOSE Software. J. Biomed. Phys. Eng. 2019, 9, 285–294. [Google Scholar] [CrossRef]
- Zhao, L.; Liu, C.; Xing, Y.; He, J.; O’Doherty, J.; Huang, W.; Zhao, J. Development of a 99mTc-Labeled Single-Domain Antibody for SPECT/CT Assessment of HER2 Expression in Breast Cancer. Mol. Pharm. 2021, 18, 3616–3622. [Google Scholar] [CrossRef]
- Ahlgren, S.; Wållberg, H.; Tran, T.A.; Widström, C.; Hjertman, M.; Abrahmsén, L.; Berndorff, D.; Dinkelborg, L.M.; Cyr, J.E.; Feldwisch, J.; et al. Targeting of HER2-Expressing Tumors with a Site-Specifically 99mTc-Labeled Recombinant Affibody Molecule, ZHER2:2395, with C-Terminally Engineered Cysteine. J. Nucl. Med. 2009, 50, 781–789. [Google Scholar] [CrossRef]
- Mitran, B.; Thisgaard, H.; Rosenström, U.; Dam, J.H.; Larhed, M.; Tolmachev, V.; Orlova, A. High Contrast PET Imaging of GRPR Expression in Prostate Cancer Using Cobalt-Labeled Bombesin Antagonist RM26. Contrast Media Mol. Imaging 2017, 2017, 6873684. [Google Scholar] [CrossRef]
Organ | [99mTc]Tc-BQ0413 (40 pmol) | [99mTc]Tc-BQ0413 (40 pmol) + BQ0413 (5 nmol) | [99mTc]Tc-BQ0413 (40 pmol) + PSMA-11 (5 nmol) |
---|---|---|---|
Blood | 0.32 ± 0.05 a | 0.11 ± 0.02 | 0.13 ± 0.03 |
Salivary gland | 2.3 ± 0.3 a,b | 0.27 ± 0.07 | 0.3 ± 0.07 |
Lungs | 1.8 ±0.3 a,b | 0.25 ± 0.06 | 0.24 ± 0.04 |
Liver | 0.43 ± 0.07 a,b | 0.15 ± 0.04 | 0.21 ± 0.06 |
Spleen | 13 ± 3 a,b | 1.0 ± 0.2 | 0.85 ± 0.05 |
Pancreas | 1.1 ± 0.2 a,b | 0.15 ± 0.04 | 0.11 ± 0.02 |
Stomach | 0.5 ± 0.1 | 0.3 ± 0.1 | 0.2 ± 0.1 |
Small intestine | 0.3 ± 0.1 b | 0.11 ± 0.09 | 0.19 ± 0.03 |
Kidneys | 241 ± 21 a,b | 12 ± 2 c | 57 ± 2 |
Tumor | 38 ± 6 | 33 ± 3 | 31 ± 4 |
Muscle | 0.3 ± 0.1 | 0.06 ± 0.02 | 0.07 ± 0.02 |
Bone | 0.5 ± 0.1 | 0.4 ± 0.2 | 0.5 ± 0.1 |
Intestines with content * | 2.0 ± 0.2 | 1.7 ± 0.2 | 1.7 ± 0.1 |
Carcass * | 8.4 ± 0.7 | 2.3 ± 0.9 | 2 ± 2 |
Organ | [99mTc]Tc-BQ0413 (40 pmol) | [99mTc]Tc-BQ0413 (40 pmol) + BQ0413 (5 nmol) | [99mTc]Tc-BQ0413 (40 pmol) + PSMA-11 (5 nmol) |
---|---|---|---|
Blood | 123 ± 25 a | 314 ± 73 | 253 ± 48 |
Salivary gland | 16 ± 2 a,b | 127 ± 20 | 106 ± 25 |
Lungs | 21 ± 4 a,b | 134 ± 30 | 133 ± 21 |
Liver | 85 ± 5 a | 222 ± 55 | 159 ± 41 |
Spleen | 2.8 ± 0.5 a,b | 35 ± 6 | 37 ± 5 |
Pancreas | 39 ± 9 a,b | 235 ± 50 | 293 ± 45 |
Stomach | 69 ± 6 | 146 ± 73 | 171 ± 93 |
Small intestine | 106 ± 20 | 393 ± 191 | 170 ± 47 |
Kidneys | 0.20 ± 0.02 a,b | 2.8 ± 0.4 c | 0.5 ± 0.1 |
Muscle | 123 ± 36 b | 539 ± 165 | 469 ± 103 |
Bone | 67 ± 11 | 80 ± 28 | 74 ± 24 |
Targeted Organ | Absorbed Dose (mGy/MBq) |
---|---|
Adrenals | 0.0069 |
Brain | 0.0004 |
Gallbladder wall | 0.0041 |
Lower large intestine wall | 0.0010 |
Small intestine wall | 0.0024 |
Stomach wall | 0.0028 |
Upper large intestine LI wall | 0.0024 |
Heart wall | 0.0017 |
Kidneys | 0.1170 |
Liver | 0.0030 |
Lungs | 0.0012 |
Muscle | 0.0013 |
Pancreas | 0.0051 |
Red bone marrow | 0.0019 |
Osteogenic cells | 0.0024 |
Skin | 0.0006 |
Spleen | 0.0068 |
Testes | 0.0004 |
Thymus | 0.0007 |
Thyroid | 0.0005 |
Urinary bladder | 0.0007 |
Uterus | 0.0011 |
Total body | 0.0018 |
Effective dose equivalent (mSv/MBq) | 0.0092 |
Effective dose (mSv/MBq) | 0.0018 |
Tracer | Equilibrium Dissociation Constant, KD | Reference |
---|---|---|
[177Lu]Lu-PSMA-617 | 0.24 nM | [24] |
[18F]F-DCFPyL | 0.49 ± 0.04 nM | [25] |
Al [18F]F-PSMA-BCH | 2.9 ± 0.8 nM | [26] |
[18F]F-PSMA-11 | 3.0 ± 0.9 nM | [27] |
[68Ga]Ga-PSMA-11 | 0.5 ± 0.2 nM | [27] |
[99mTc]Tc-PSMA-T1 [99mTc]Tc-PSMA-T4 | 11.4 nM | [18] |
[99mTc]Tc-MIP-1427 [99mTc]Tc-MIP-1404 [99mTc]Tc-MIP-1428 [99mTc]Tc-MIP-1405 | 0.6 ± 0.4 nM 1.1 ± 0.9 nM 1.8 ± 0.3 nM 4.3 ± 0.3 nM | [11] |
Tracer | Effective Dose (mSv/MBq) | Reference |
---|---|---|
[99mTc]Tc-PSMA I&S | 0.0055 * | [20] |
[99mTc]Tc-HYNIC-PSMA | 0.0003 * | [39] |
[99mTc]Tc-HYNIC-PSMA-XL-2 | 0.0048 * | [40] |
[99mTc]Tc-maSSS-PEG2-RM26 | 0.0035 # | [41] |
[99mTc]Tc-ADAPT6 | 0.009 * | [42] |
[99mTc]Tc-DTPATc-DTPA | 0.0175 * | [43] |
[99mTc]Tc-NM-02 | 0.0065 * | [44] |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Bezverkhniaia, E.; Kanellopoulos, P.; Abouzayed, A.; Larkina, M.; Oroujeni, M.; Vorobyeva, A.; Rosenström, U.; Tolmachev, V.; Orlova, A. Preclinical Evaluation of a Novel High-Affinity Radioligand [99mTc]Tc-BQ0413 Targeting Prostate-Specific Membrane Antigen (PSMA). Int. J. Mol. Sci. 2023, 24, 17391. https://doi.org/10.3390/ijms242417391
Bezverkhniaia E, Kanellopoulos P, Abouzayed A, Larkina M, Oroujeni M, Vorobyeva A, Rosenström U, Tolmachev V, Orlova A. Preclinical Evaluation of a Novel High-Affinity Radioligand [99mTc]Tc-BQ0413 Targeting Prostate-Specific Membrane Antigen (PSMA). International Journal of Molecular Sciences. 2023; 24(24):17391. https://doi.org/10.3390/ijms242417391
Chicago/Turabian StyleBezverkhniaia, Ekaterina, Panagiotis Kanellopoulos, Ayman Abouzayed, Mariia Larkina, Maryam Oroujeni, Anzhelika Vorobyeva, Ulrika Rosenström, Vladimir Tolmachev, and Anna Orlova. 2023. "Preclinical Evaluation of a Novel High-Affinity Radioligand [99mTc]Tc-BQ0413 Targeting Prostate-Specific Membrane Antigen (PSMA)" International Journal of Molecular Sciences 24, no. 24: 17391. https://doi.org/10.3390/ijms242417391